Abstract:Celiac disease (CD) is an autoimmune disorder exacerbated by the ingestion of gluten in genetically susceptible individuals, leading to intestinal inflammation and damage. This chronic disease affects approximately 1% of the world’s population and is a growing health challenge due to its increasing prevalence. The development of CD is a complex interaction between genetic predispositions and environmental factors, especially gluten, culminating in a dysregulated immune response. The only effective treatment at present is a strict, lifelong gluten-free diet. However, adherence to this diet is challenging and often incomplete, so research into alternative therapies has intensified. Recent advances in understanding the molecular and immunological aspects of CD have spearheaded the development of novel pharmacologic strategies that should provide more effective and manageable treatment options. This review examines the latest innovations in CD therapies. The focus is on drugs in advanced clinical phases and targeting specific signaling pathways critical to the disease pathogenesis. We discuss both quantitative strategies such as enzymatic degradation of gluten, and qualitative approaches including immunomodulation and induction of gluten tolerance. Innovative treatments currently under investigation include transglutaminase inhibitors, which prevent the modification of gluten peptides, and nanoparticle-based therapies to recalibrate the immune response. These new therapies not only promise to improve patient outcomes but are also expected to improve quality of life by reducing the burden of dietary restrictions. The integration of these new therapies could revolutionize the treatment of CD and shift the paradigm from strict dietary restrictions to a more flexible and patient-friendly therapeutic approach. This review provides a comprehensive overview of the future prospects of CD treatment and emphasizes the importance of continued research and multidisciplinary collaboration to integrate these advances into standard clinical practice.

Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease

The global burden of coeliac disease: opportunities and challenges

Frontiers in Celiac Disease: Where Autoimmunity and Environment Meet

Evolution in coeliac disease diagnosis and management

Advances in understanding and managing celiac disease: Pathophysiology and treatment strategies

A look into the future: Are we ready for an approved therapy in celiac disease?

An updated overview on celiac disease: from immuno-pathogenesis and immuno-genetics to therapeutic implications

Co-factors, Microbes, and Immunogenetics in Celiac Disease to Guide Novel Approaches for Diagnosis and Treatment

Tolerance-inducing therapies in coeliac disease — mechanisms, progress and future directions

Beyond the gluten-free diet: Innovations in celiac disease therapeutics

Celiac Disease: Against the Grain in Gastroenterology

Celiac disease 2015 update: new therapies

Challenges to drug discovery for celiac disease and approaches to overcome them

Emergence of an adaptive immune paradigm to explain celiac disease: a perspective on new evidence and implications for future interventions and diagnosis

"Coelionomics": towards understanding the molecular pathology of coeliac disease

How future pharmacological therapies for celiac disease will complement the gluten-free diet

Celiac disease gut microbiome studies in the third millennium: reviewing the findings and gaps of available literature

Coeliac Disease Pathogenesis: The Uncertainties of a Well-Known Immune Mediated Disorder

Celiac Disease and Neurological Manifestations: From Gluten to Neuroinflammation

Review article: Follow-up of coeliac disease

Potential Make-or-Break Determinants of Celiac Disease